Brain-Computer Interface Rehabilitation Device Company Establishes in Nanjing; 'Breathable' Endovascular Stent Graft Secures EU Certification

1. The National Healthcare Security Administration promotes the basic unification of medical service price items across China.

Recently, the National Healthcare Security Administration held the "Price Establishment Empowering Medical Technology Innovation and Development Sharing Event." Nearly 200 representatives from relevant departments, local healthcare security departments, medical institutions, university associations, investment institutions, and medical device companies attended the event. More than 20 companies showcased dozens of medical devices on-site. It is reported that next, the National Healthcare Security Administration will comprehensively complete the compilation of the project establishment guidelines, promote the basic unification of medical service price items across China, start to improve the management methods for new medical service price projects, explore the pre-establishment pricing process, guide regions to enhance the quality and efficiency of accepting and reviewing new price projects, accelerate clinical transformation, stabilize market expectations, and ensure that the public can access high-quality, efficient, and affordable medical services. (Guangzhou Daily)

2. Medtronic Partners with Kossel Medtech

Recently, Kossel Medtech (Suzhou) Co., Ltd. and Medtronic (Shanghai) Management Co., Ltd. held a grand strategic cooperation signing ceremony. This collaboration marks the official establishment of an in-depth strategic partnership between the two parties, focusing on the core product of Kossel's subsidiary, Mixin Medical Technology (Suzhou) Co., Ltd., the Seledora® Coronary Cutting Balloon Dilation Catheter, to initiate profound synergies. Together, they aim to promote the clinical application of this innovative medical technology, benefiting a broader population of patients with coronary heart disease. As a local innovative enterprise deeply rooted in the field of vascular intervention, Kossel has always been guided by clinical needs, concentrating on the research, development, and transformation of high-end medical devices. The self-developed Seledora® Cutting Balloon, with its unique technical design, overcomes traditional treatment bottlenecks, providing precise solutions for the treatment of complex coronary diseases such as moderate to severe calcified lesions. (Medical Device News)

3. Chinese research team collaborates to create "human-machine symbiosis" self-powered micro heart pacemaker

Chinese Research Team Develops Capsule-Sized Symbiotic Self-Powered Leadless Cardiac PacemakerA research team comprising multiple institutions, including the University of Chinese Academy of Sciences, Tsinghua University/Beijing Tsinghua Changgung Hospital, and Peking University/Peking University Third Hospital, has successfully developed a capsule-sized symbiotic self-powered leadless cardiac pacemaker. The pacemaker captures kinetic energy from heartbeats using electromagnetic induction technology and converts it into electrical energy. Its output power has surpassed the energy threshold required for lifelong operation, enabling stable driving of the pacing circuit to achieve precise regulation of heart rhythm. The highly miniaturized design demonstrates excellent biocompatibility and hemocompatibility, supporting minimally invasive transcatheter implantation, significantly reducing surgical trauma. An innovative magnetically suspended energy storage structure reduces energy loss and mechanical friction, enhancing the long-term stability of the device. (Sina News)

4. Brain-Computer Interface Rehabilitation Device Company Settles in Nanjing

Recently, Huaweilink, a wholly-owned subsidiary of Nanjing Huawei Medical, has settled in Qixia, focusing on the innovative application and industrialization of brain-computer interface technology in the field of neurorehabilitation. The company plans to invest over 150 million yuan in five years for core R&D team salaries, equipment procurement, etc., demonstrating its determination to deeply cultivate the industry. Huaweilink has built a full-stack self-developed technology system with complete intellectual property rights for key equipment. Its signal acquisition and algorithm decoding capabilities have reached an internationally advanced level. It has established in-depth cooperation with multiple top universities and hospitals to jointly build a closed-loop verification platform. In addition, the company has set up a digital R&D management system to solve the problems of long R&D cycles and complex registration processes. It plans to obtain 20 Class II or above medical device registration certificates within two years and build a brain-computer interface rehabilitation product matrix. (Ths.cn Finance)

5. Hebei Province Medical Science and Technology Achievements Transfer and Transformation Innovation Competition Launches

Recently, the Hebei Province Medical Science and Technology Achievements Transfer and Transformation Innovation Competition was launched, simultaneously establishing a scientific and technological achievements repository in the medical and health field. The competition, themed "Medical Innovation, Sparking a Prairie Fire," includes projects that have obtained intellectual property rights or completed national certification of scientific and technological achievements, divided into three categories: medical technology, medical devices, and biomedicine. Projects must comply with regulations and policies and have no intellectual property disputes. The competition consists of two stages: the preliminary round (March 2026, selecting the best through peer review and market value assessment) and the final round (April 2026, live roadshows and defense reviews), with first, second, third prizes, and an organizational award. During this period, the achievements repository will be established simultaneously; winning projects will be directly included in the repository, and some non-winning but promising projects may also be included. Winning achievements will receive priority recommendations for project approval, research funding, and other support, along with incubation services. (Jintai News)

6. "Breathable" Covered Stent Passes EU Certification

Recently, the Talos®/Tongtianyan™ Straight Tubular Thoracic Aortic Stent Graft System developed by Shanghai MicroPort CardioFlow Medtech™ has successfully obtained the EU CE MDR certification. Thus far, MicroPort CardioFlow Medtech™ has achieved this certification for six of its products, further strengthening its global presence. This stent graft is a "breathing" stent designed for surgical treatment of Stanford Type B aortic dissection. Its unique distal fenestrated structure can expand the true lumen of the distal thoracic aorta, reduce the risk of spinal ischemia, and improve long-term treatment outcomes. Available in lengths of up to 260mm, it better supports the true lumen of the aorta, achieving superior remodeling. The product was approved to enter the National Innovative Medical Device Special Review Process in 2017, received market approval in China in 2022, and has since been clinically applied in over 500 hospitals across China as well as in multiple countries in Latin America. (Innovative Medical Device Network)

7. R&D Design Services Accelerate the Clinical Transformation of Medical Research Achievements

Medical device research and development is a complex and rigorous process, involving multiple aspects such as technology, regulations, and clinical trials. Ossonda has a 20,000-square-meter science and innovation center and has established a medical device research institute dedicated to the clinical transformation of medical scientific research achievements. It has a high-level, international professional multidisciplinary team proficient in the entire process of R&D, regulations, clinical trials, registration, and production, capable of conducting R&D and production of various complex innovative products. With rich project experience and industry resources, it has built a standardized, regulated, and digitalized full-process service system. It provides one-stop services from preliminary market research, product concept generation, product design and development to prototype production and testing. To date, Ossonda has had more than 200 projects enter the review stage, over 100 projects under development, with a 100% success rate in transformation. (Compiled by Ossonda)

8. A-share listed company invests in a brain-computer interface

Recently, Biotron Bio, an IVD track listed company, completed an exclusive strategic investment in Haoshi Tianhui, a brain-computer interface company. The financing amount was not disclosed. The investment round was a strategic investment, with Biotron Bio as the investment institution; no financial advisor was mentioned. Haoshi Tianhui, founded by Chen Hao, is a high-tech enterprise in the field of AI brain health assessment and intervention. Its developed non-invasive brain-computer interface and mental health assessment devices can accurately evaluate emotional issues and integrate intervention solutions. Biotron Bio, established in 2008, was listed on the Shanghai Stock Exchange in 2021. In recent years, it has increased its focus on brain-computer interface technology. In 2025, Biotron Bio invested in Haoshi Tianhui to enter this field, becoming a brain-computer interface concept stock in the IVD track. After Musk announced at the beginning of the year that brain-computer interface products were expected to be mass-produced, Biotron Bio's shares rose 20% in a single day. (Intelligent Medicine Bureau)